Groundbreaking Innovation Receives TGA Approval in Australia.
We are thrilled to announce a significant milestone in orthopedic innovation: ReCerf®, an advanced, all-ceramic bearing technology designed to treat worn osteoarthritic hips, has received approval from the Therapeutic Goods Administration (TGA) in Australia.
This landmark approval represents the first regulatory authorisation of its kind globally.
The TGA approval paves the way for ReCerf to transform the standard of care for osteoarthritic hip treatment, marking a new chapter in patient-focused innovation. This achievement underscores our commitment to advancing orthopedic solutions that improve quality of life.
For more information or to stay updated on ReCerf®, visit our dedicated website at www.ReCerf.com. If you'd like to learn more or register your interest, please complete the contact form on our website.
Please note: ReCerf® is not yet on general release with CE approval (MatOrtho® is a UK-based company), and its availability worldwide is subject to local regulatory and hospital approvals. Unfortunately, the time from application to approval is not in our control and can vary between countries and hospitals.
When approved, ReCerf® will be available for patients who meet criteria determined by the surgeons, all of whom are world experts in hip replacement and hip resurfacing. Such criteria are part of a safe and responsible approach to introducing new technologies and are defined for the benefit of everyone, particularly patients.
We as a manufacturer are not able to comment on any individual circumstances, however, we are in contact with and supporting the surgeons who will access ReCerf® when it becomes available in their region.